An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Twist Bioscience Corporation (NASDAQ: TWST) will announce its financial results for the first quarter of fiscal 2022, ending December 31, 2021, before the market opens on February 4, 2022. A conference call will be held at 8:00 a.m. ET to discuss these results and provide business updates. Investors can access the press release on the company's website prior to the call. Twist Bioscience, known for its silicon-based DNA synthesis platform, continues to innovate in synthetic biology, with applications across multiple industries including healthcare and agriculture.
Positive
Twist is a leading company in synthetic biology with growing applications.
The upcoming financial results announcement could provide insights into revenue growth.
Negative
None.
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 first quarter ended December 31, 2021, before the opening of the market on Friday, February 4, 2022. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.
The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 3886933. A telephonic replay of the conference call will be available beginning approximately four hours after the call through February 11, 2022 and may be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay conference ID is 3886933. The webcast replay will be available for two weeks.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
